Navigation Links
Plexus Systems, Inc. and Aberdeen Group Co-host March 27 Webinar on Manufacturing Efficiency
Date:3/25/2008

e resource planning (ERP) functions such as accounting and finance modules, customer relationship management (CRM) features such as order entry and tracking, manufacturing execution systems (MES) functions such as production scheduling and machine integration and supply chain management (SCM) functions such as supplier quality and traceability.

About Aberdeen Group, a Harte-Hanks Company

Aberdeen is a leading provider of fact-based research and market intelligence that delivers demonstrable results. Having benchmarked more than 30,000 companies in the past two years, Aberdeen is uniquely positioned to educate users to action: driving market awareness, creating demand, enabling sales, and delivering meaningful return-on-investment analysis. As the trusted advisor to the global technology markets, corporations turn to Aberdeen(TM) for insights that drive decisions. For additional information, visit Aberdeen http://www.aberdeen.com.

About Plexus Systems, Inc.

Since 1995, Plexus Systems, Inc. (Auburn Hills, Mich.) has maintained a singular vision -- to drive significant cost, quality and productivity improvements for manufacturers, from the shop floor to the top floor. Plexus Online(TM) is an on-demand software for the manufacturing enterprise. Plexus Systems originated as an internal solution at a manufacturing company, designed to resolve quality challenges, including production, distribution and global supply chains management issues. Today, Plexus Online enables businesses to manage accounting, financials, compliance and human resources and other critical priorities. Plexus Systems serves a global cross section of manufacturing industries (OEM and suppliers), particularly automotive, defense, medical device and aerospace companies. In 2006, Apax Partners (http://www.apax.com) made a strategic investment in Plexus Systems, joining the foundi
'/>"/>

SOURCE Plexus Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
2. Plexus Systems, Inc. Names Khanna to Senior Account Manager - Western Region
3. Plexus Systems, Inc. Names Stosz to Solutions Engineer
4. Plexus Systems, Inc. Announces Participation at AM EXPO
5. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
6. Arbios Systems, Incs Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
7. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
8. Mediware Information Systems, Inc. Receives Notice from the Nasdaq Stock Market
9. FDA Grants Clearance to Langford IC Systems, Inc.
10. Four Rivers Software Systems, Inc. Announces the Promotion of Samantha Rouse to Senior Vice President of Product and Services
11. CAS Medical Systems, Inc. Ranked Among Connecticuts Fastest Growing Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...ombining natural organic atoms with metal complexe...ed a new type of enzyme inhibitor capable of block... cancer development. , Based on studies in huma...eveloping new ways to treat cancer by dampening th...olled tumor growth. , Details of the study, to b...
(Date:5/15/2008)...ay 15 /PRNewswire-FirstCall/ -- Lung cancer patien...sions may fare better as a,result, according to da...C),clinical trial. Data from the trial, which invo... for injection), will be presented at the 44th Ann...cology (ASCO) in Chicago,Ill., May 30 -- June 3, ...
(Date:5/15/2008)...ity-control audit of community hospitals associate...gests that a partnership between a major academic ...are created, and community hospitals, where most c...uickly and effectively disseminating advances in c...d Comprehensive Cancer Center in Philadelphia, fir...
(Date:5/15/2008)...motherapy given in conjunction with cancer vaccine...ly improving the effectiveness of this promising t...earchers in the Duke Comprehensive Cancer Center. ...ls that suppress immune function and we speculated...used in conjunction with vaccines, which work by b...
Breaking Medicine News(10 mins):Health News:Novel enzyme inhibitor paves way for new cancer drug 2Health News:Novel enzyme inhibitor paves way for new cancer drug 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 2Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 4Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 5Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 6Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 7Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 2Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 3Health News:Chemotherapy might help cancer vaccines work 2
... Agreement with Laboratoire Physcience, France, fo...ibra(R)//, as a single dose mini-shot, in France, ...ssfully launched its Slim 10/10 product into these... successful ever product launch into the French ma...
...ering from symptoms of hypertension in the young d...consequences// of hypertension as they become adul... and found that prehypertension leads to hypertens...alkner, MD, professor of medicine and pediatrics a...
...lled antisense drugs, which can block the genes as...til now, it has been difficult for scientists to f...vented from breaking down before they reach the ta...e overcome by combining the drugs with small gold ...
...r more drugs made by a Heilongjiang Province drug ...ed with a poisonous industrial chemical. // It w...cal hospital in Guangzhou, capital city of south's... have shown symptoms of acute renal failure after ...
Other Medicine News:Health News:Prehypertension in the Young Leads to Hypertensive Adults 2Health News:Anti-Sense Drugs and Nanotechnology Offer New Hope In Cancer Fight 2Health News:Investigators Find Poisonous Chemicals In Four More Drugs In China 2
(Date:5/15/2008)... GREEN BAY, Wis., May 15 /- Omeg... be further considered as a credible natural,alter...ty in ADHD patients,recent in vivo French study r...cial effects of omega-3 in hyperactivity, French r...ld have specific positive effects on,impulse contr...
(Date:5/14/2008)... CAMBRIDGE, Mass., May 14 /PRNewswire-FirstCa...announced that the results from its Phase II coron... the peer-reviewed,EuroIntervention Journal. The p...te haemoglobin based oxygen therapeutics in electi...ale, protocol design, and haemodynamic,results." T...
(Date:5/14/2008)... Believed by experts to be important for cer...RNewswire-FirstCall/ -- New data from an,extended ...GSK ) cervical,cancer candidate vaccine, CERVARIX(... antibodies against the two most common cervical c... 6.4 years. This is the longest,duration of sustai...
(Date:5/14/2008)... Data Presented at the American Society of Hyp...ual Scientific Meeting - A cumulative forty-fiv...nsion treated with a regimen of BENICAR(R) (olmesa...medoxomil/hydrochlorothiazide) achieved ... Eight out of 10 (cumulative 81%) patients with st...
Breaking Medicine Technology:Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 2Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7Weill Cornell science briefs May 2008 19346 1Weill Cornell science briefs May 2008 19346 2Weill Cornell science briefs May 2008 19346 3Weill Cornell science briefs May 2008 19346 4Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 1Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 2Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 3Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 4Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 5Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 6Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 7Kresge Foundation Employs New Funding Methods in its First Quarter Grant Awards of Nearly 2443 Million 19344 8Saia Partners with Susan G Komen for the Cure 19339 1Saia Partners with Susan G Komen for the Cure 19339 2Saia Partners with Susan G Komen for the Cure 19339 3Milliman Says 2008 Medical Cost for American Family of Four Exceeds 2415 600 19334 1Milliman Says 2008 Medical Cost for American Family of Four Exceeds 2415 600 19334 2
...007 /PRNewswire-FirstCall/ -- Kosan,Biosciences In...,proprietary nuclear export inhibitors (NEI) showi...ng anticancer activity with a,high degree of toler...odels. , Kosan,s NEIs are potent, specific inhibit... that exports key regulatory proteins,("cargo" pro...
...sion Proteins Made by Combining,Cytokines With Per...Anti-Tumor Activity With No Observable Toxicity -,...RNewswire-FirstCall/ -- Peregrine Pharmaceuticals,... developing targeted,monoclonal antibodies for the...on, today reported that data presented at the,Cent...
Other Medicine Technology:Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 4Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 2Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 3Data Presented at AACR Meeting Shows Peregrine's Immunocytokine,Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in,Preclinical Studies 4
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption.
Lyphochek Tumor Marker Control is a comprehensive, bilevel product designed to assess the performance of various cancer antigen tests, including esoteric tumor markers.
Lyphochek Maternal Serum Control is a trilevel product with analytes at clinically significant levels to monitor maternal serum analysis.
Lyphochek Immunoassay Plus Control provides the clinical laboratory with the most comprehensive control in the world for monitoring immunoassay and therapeutic drug monitoring procedures, eliminating
Medicine Products: